Hangzhou Highlightll Pharmaceutical Co., Ltd
Clinical trials sponsored by Hangzhou Highlightll Pharmaceutical Co., Ltd, explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New arthritis drug TLL-018 moves to Long-Term safety check in 350 patients Results expected Dec 2026 (estimated)
- New eczema ointment shows promise in early trial Results expected Jun 2027 (estimated)
- Can a new pill tame rheumatoid arthritis when standard drugs fail? Results expected Jul 2027 (estimated)
-
New RA pill takes on tofacitinib in Head-to-Head trial
Disease control OngoingThis phase 3 trial tests whether a new oral drug called TLL-018 works better than tofacitinib for active rheumatoid arthritis. The study includes 459 adults aged 18-65 who have not responded well to or cannot tolerate biologic treatments. Participants take either TLL-018 or tofac…
Phase 3 • Sponsor: Hangzhou Highlightll Pharmaceutical Co., Ltd • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
New hope for chronic hive sufferers: phase 3 drug trial shows promise
Symptom relief OngoingThis study tests a new drug called TLL-018 in 440 adults with moderate-to-severe chronic hives (chronic spontaneous urticaria) that aren't controlled by standard antihistamines. Participants receive either TLL-018 or a placebo for 12 weeks to see if it reduces itching and hives b…
Phase 3 • Sponsor: Hangzhou Highlightll Pharmaceutical Co., Ltd • Aim: Symptom relief
Last updated Jun 27, 2026 13:00 UTC